Paris, FRANCE (OBBeC) - ExonHit Therapeutics, a drug and diagnostic discovery company, has announced the availability of its new SpliceArray for use in disease modelling and toxicogenomic applications by the basic and pre-clinical research communities. The new patented technology is now offered through the Company's portfolio of genomic services.

The Rat SpliceArray monitors over 23,000 genes utilizing over 200,000 exon body and 180,000 splice junction regions. This comprehensive coverage enables investigators to further elucidate the enormous diversity of the rat transcriptome. These new designs, manufactured on the Agilent Technologies and Affymetrix microarray platforms, enable researchers to leverage alternative splicing discovery in the rat model system.

"ExonHit continues to grow its catalogue of arrays for it genomics services. This most recent addition will expand our ability to service clients who use rat models in elucidating disease biology, as well as for ExonHit's discovery collaboration programs for therapeutic targets and safety biomarkers" said John R. Jaskowiak, Executive Vice President of Molecular Diagnostics and Genomics Services at ExonHit Therapeutics.